AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17566099 — intervention group
Group type: EXPERIMENTAL
Intervention: ghrelin and CRH with l-arginine
Number of subjects: 10
Study 17566099 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 10
Study 15810767 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group practiced the skill with the hand opposite the one used during the pretest until they reached a designated criterion for their age.
Number of subjects: 160
Study 15810767 — intervention group
Group type: COMPARATOR
Intervention: Control group performed a balancing activity.
Number of subjects: 160
Study 12556542 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 281
Study 12556542 — intervention group
Group type: COMPARATOR
Intervention: Off-pump surgery
Number of subjects: 281
Study 11074392 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of surgery for subarachnoid haemorrhage (SAH)
Number of subjects: 0
Study 11074392 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy (TURP)
Number of subjects: 0
Study 11074392 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 8898143 — intervention group
Group type: EXPERIMENTAL
Intervention: Local corticosteroid injections
Number of subjects: 106
Study 8898143 — intervention group
Group type: COMPARATOR
Intervention: Cyriax-type physiotherapy
Number of subjects: 106
Study 1651304 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 187
Study 1651304 — intervention group
Group type: COMPARATOR
Intervention: Chest irradiation alone
Number of subjects: 187
Study 1651304 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chest irradiation alone
Number of subjects: 187
Study 6152880 — intervention group
Group type: COMPARATOR
Intervention: Beta-receptor blockade continued until surgery (n = 48)
Number of subjects: 91
Study 6152880 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-receptor blockade gradually withdrawn (n = 51)
Number of subjects: 91
Study 31478300 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medications
Number of subjects: 138
Study 31478300 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging behaviour
Number of subjects: 138
Study 30835307 — intervention group
Group type: COMPARATOR
Intervention: Placebo without therapy (n=257)
Number of subjects: 1025
Study 30835307 — intervention group
Group type: COMPARATOR
Intervention: Placebo with therapy (n=256)
Number of subjects: 1025
Study 30835307 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplements without therapy (n=256)
Number of subjects: 1025
Study 30835307 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplements with therapy (n=256)
Number of subjects: 1025
Study 29039320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg fast dispersible tablets (test)
Number of subjects: 12
Study 29039320 — intervention group
Group type: COMPARATOR
Intervention: Marketed (reference) product
Number of subjects: 12
Study 25652579 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy for insomnia
Number of subjects: 80
Study 25652579 — intervention group
Group type: COMPARATOR
Intervention: Internet-based control program
Number of subjects: 80
Study 24352348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine or abacavir
Number of subjects: 0
Study 24352348 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine plus lamivudine
Number of subjects: 0
Study 21561896 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 infusion at 1.2 pmol/kg/min starting 30 min before dobutamine stress echocardiography (DSE)
Number of subjects: 14
Study 21561896 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 infusion
Number of subjects: 14
Study 21561896 — intervention group
Group type: COMPARATOR
Intervention: Control (no GLP‐1 infusion)
Number of subjects: 14
Study 19571733 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI substudy enrollers
Number of subjects: 327
Study 19571733 — intervention group
Group type: COMPARATOR
Intervention: Nonenrollers
Number of subjects: 327
Study 17475965 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET/CT with delayed images after furosemide and oral hydration
Number of subjects: 17
Study 10721881 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 24
Study 10721881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8836320 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural auditory stimuli with ISIs of 0.5, 1.0, and 10.0 s
Number of subjects: 50
Study 1579628 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam (6 mg)
Number of subjects: 30
Study 1579628 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam (12 mg)
Number of subjects: 30
Study 1579628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1579628 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam (6 mg and 12 mg)
Number of subjects: 30
Study 4040550 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (120 mg/m2)
Number of subjects: 64
Study 4040550 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cisplatin (60 mg/m2)
Number of subjects: 64
Study 31319633 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT in liquid form (MCT-L)
Number of subjects: 29
Study 31319633 — intervention group
Group type: COMPARATOR
Intervention: LCT in liquid form (Con-L)
Number of subjects: 29
Study 31319633 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT in solid form (MCT-S)
Number of subjects: 29
Study 31319633 — intervention group
Group type: COMPARATOR
Intervention: LCT in solid form (Con-S)
Number of subjects: 29
Study 30204905 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 iso-energetic breakfasts
Number of subjects: 15
Study 30204905 — intervention group
Group type: COMPARATOR
Intervention: Energy-free control meal
Number of subjects: 15
Study 27476722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0
Study 24715249 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA + standard of care
Number of subjects: 273
Study 24715249 — intervention group
Group type: COMPARATOR
Intervention: placebo + standard of care
Number of subjects: 273
Study 23431840 — intervention group
Group type: EXPERIMENTAL
Intervention: Video presentation group
Number of subjects: 66
Study 23431840 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated book group
Number of subjects: 66
Study 23431840 — intervention group
Group type: EXPERIMENTAL
Intervention: Both video presentation and illustrated book group
Number of subjects: 66
Study 23431840 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 20920261 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol lozenges
Number of subjects: 691
Study 20920261 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 691
Study 18823202 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gaze sampling with natural looking patterns
Number of subjects: 0
Study 18823202 — intervention group
Group type: COMPARATOR
Intervention: Unnatural looking patterns
Number of subjects: 0
Study 15932659 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 40 mg/d
Number of subjects: 88
Study 15932659 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 88
Study 12460700 — intervention group
Group type: EXPERIMENTAL
Intervention: CC genotype in white participants with treated hypertension
Number of subjects: 2171
Study 12460700 — intervention group
Group type: COMPARATOR
Intervention: AA genotype in white participants with treated hypertension
Number of subjects: 2171
Study 12460700 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 2171
Study 12460700 — intervention group
Group type: EXPERIMENTAL
Intervention: CC genotype in white participants
Number of subjects: 2171
Study 10342710 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 200 mg/d
Number of subjects: 21
Study 10342710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7500633 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece/noseclip (BV)
Number of subjects: 10
Study 7500633 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth/face mask (MM)
Number of subjects: 10
Study 7500633 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask (FM)
Number of subjects: 10
Study 7500633 — intervention group
Group type: COMPARATOR
Intervention: Mouthpiece/noseclip (BV), Mouth/face mask (MM), Facemask (FM)
Number of subjects: 10
Study 1773202 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone
Number of subjects: 10
Study 1773202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31758564 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intervention plus booster email
Number of subjects: 537
Study 31758564 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intervention only
Number of subjects: 537
Study 31758564 — intervention group
Group type: COMPARATOR
Intervention: General health education
Number of subjects: 537
Study 31205435 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 28
Study 31205435 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 28
Study 29926711 — intervention group
Group type: COMPARATOR
Intervention: 20 μg HBV vaccine
Number of subjects: 39
Study 29926711 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μg HBV vaccine
Number of subjects: 39
Study 26542491 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide (1.8 mg before intervention, followed by 0.6 mg for 2 days, 1.2 mg for 2 days, and 1.8 mg for 3 days)
Number of subjects: 92
Study 26542491 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 92
Study 26542491 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 92
Study 23524424 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable glass-ionomer cement (GIC) as a liner in proximal-ART restorations; two-layer technique with Ketac Molar Easymix; operators had no experience or two years of experience, both trained for one week.
Number of subjects: 45
Study 21939561 — intervention group
Group type: EXPERIMENTAL
Intervention: ε4 carriers
Number of subjects: 1402
Study 21939561 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers of ε4 allele
Number of subjects: 1402
Study 21939561 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1402
Study 21118564 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise programme
Number of subjects: 0
Study 21118564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-moderate intensity exercise programme
Number of subjects: 0
Study 21118564 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 17690713 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen-specific therapies
Number of subjects: 0
Study 17690713 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental models and clinical trials
Number of subjects: 0
Study 17690713 — intervention group
Group type: EXPERIMENTAL
Intervention: Advances in antigen-specific therapies
Number of subjects: 0
Study 15611327 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention Foster Care Program (EIFC)
Number of subjects: 0
Study 15611327 — intervention group
Group type: COMPARATOR
Intervention: Regular foster care comparison condition
Number of subjects: 0
Study 12169965 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 60
Study 12169965 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 60
Study 10628519 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertiveness building prevention program
Number of subjects: 206
Study 10628519 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling and social inference prevention program
Number of subjects: 206
Study 10628519 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control condition
Number of subjects: 206
Study 8519716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (group 2)
Number of subjects: 38
Study 2191712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (400 mg)
Number of subjects: 43
Study 2191712 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir ophthalmic ointment (3%)
Number of subjects: 43
Study 6970007 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 35868 (Diprivan)
Number of subjects: 0
Study 6970007 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 0
Study 31775064 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily assessment schedule
Number of subjects: 307
Study 31775064 — intervention group
Group type: COMPARATOR
Intervention: Weekly assessment schedule
Number of subjects: 307
Study 31420412 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary cytoreductive surgery followed by 6 cycles of platinum-based chemotherapy
Number of subjects: 772
Study 31420412 — intervention group
Group type: COMPARATOR
Intervention: Interval cytoreductive surgery following 3 cycles of neoadjuvant chemotherapy and then 3 cycles of platinum-based chemotherapy
Number of subjects: 772
Study 25442641 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan toothpaste
Number of subjects: 438
Study 25442641 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 438
Study 23334782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg po one hour before surgery
Number of subjects: 50
Study 23334782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21335931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine thrust manipulation (TJM)
Number of subjects: 24
Study 21335931 — intervention group
Group type: COMPARATOR
Intervention: Thoracic spine thrust manipulation (TJM)
Number of subjects: 24
Study 18930378 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognition skills training intervention
Number of subjects: 31
Study 18930378 — intervention group
Group type: COMPARATOR
Intervention: Time-matched control condition (illness self-management and relapse prevention skills training)
Number of subjects: 31
Study 16508700 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg calcium plus 800 IU cholecalciferol (n=33)
Number of subjects: 64
Study 16508700 — intervention group
Group type: COMPARATOR
Intervention: 1,200 mg calcium (n=31)
Number of subjects: 64
Study 15284525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral palsy patients undergoing PSF
Number of subjects: 2
Study 15284525 — intervention group
Group type: COMPARATOR
Intervention: Idiopathic scoliosis patients undergoing PSF
Number of subjects: 2
Study 11775134 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg eprosartan
Number of subjects: 200
Study 11775134 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg eprosartan
Number of subjects: 200
Study 11775134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 8985257 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimitochondrial autoantibodies (AMA) measured by indirect immunofluorescence (IF)
Number of subjects: 0
Study 8985257 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimitochondrial autoantibodies (AMA) measured by quantitative enzyme immunoassays (EIAs)
Number of subjects: 0
Study 8985257 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels of AMA to 2‐OADC proteins
Number of subjects: 0
Study 8985257 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of AMA by IF or by quantitative EIA methods with recombinant 2‐OADC proteins
Number of subjects: 0
Study 8985257 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels of autoantibodies to 2‐OADC proteins
Number of subjects: 0
Study 8276044 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) at 0.02 microgram.kg‐1.min‐1 infusion during bypass
Number of subjects: 20
Study 8276044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGE1)
Number of subjects: 20
Study 2964340 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (P)
Number of subjects: 72
Study 2964340 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectinomycin (S)
Number of subjects: 72
Study 2964340 — intervention group
Group type: COMPARATOR
Intervention: Overall resistance to penicillin
Number of subjects: 72
Study 2964340 — intervention group
Group type: COMPARATOR
Intervention: Overall resistance to spectinomycin
Number of subjects: 72
Study 29438468 — intervention group
Group type: EXPERIMENTAL
Intervention: Variety 'Jefferson'
Number of subjects: 2
Study 29438468 — intervention group
Group type: EXPERIMENTAL
Intervention: Variety 'Jupiter'
Number of subjects: 2
Study 29438468 — intervention group
Group type: COMPARATOR
Intervention: Choice tests
Number of subjects: 2
Study 29438468 — intervention group
Group type: COMPARATOR
Intervention: No-choice tests
Number of subjects: 2
Study 29438468 — intervention group
Group type: COMPARATOR
Intervention: Choice and no-choice tests
Number of subjects: 2
Study 27029592 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartSmartKids™
Number of subjects: 33
Study 27029592 — intervention group
Group type: COMPARATOR
Intervention: Non-HeartSmartKids™
Number of subjects: 33
Study 24711047 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine
Number of subjects: 413
Study 24711047 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 413
Study 24711047 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 413
Study 24711047 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI‐1485
Number of subjects: 413
Study 24711047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 22747667 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0
Study 22747667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20573187 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 920
Study 20573187 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 920
Study 20573187 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 920
Study 18771678 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural representations learned for 3D objects
Number of subjects: 0
Study 18771678 — intervention group
Group type: EXPERIMENTAL
Intervention: View-specific representations
Number of subjects: 0
Study 15692354 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic splinting
Number of subjects: 34
Study 15692354 — intervention group
Group type: COMPARATOR
Intervention: Static splinting
Number of subjects: 34
Study 11876707 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg/day)
Number of subjects: 120
Study 11876707 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg/day) and lansoprazole (30 mg/day)
Number of subjects: 120
Study 11876707 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg/day), lansoprazole (30 mg/day), and clarithromycin (500 mg b.d.)
Number of subjects: 120
Study 10196074 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to misleading questions after viewing an event
Number of subjects: 0
Study 10196074 — intervention group
Group type: EXPERIMENTAL
Intervention: Single exposure to the event
Number of subjects: 0
Study 10196074 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple exposures to the event
Number of subjects: 0
Study 10196074 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to misinformation once or three times
Number of subjects: 0
Study 10196074 — intervention group
Group type: COMPARATOR
Intervention: Control for differences in trace strength
Number of subjects: 0
Study 8579350 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential reinforcement of incompatible behavior
Number of subjects: 0
Study 8579350 — intervention group
Group type: EXPERIMENTAL
Intervention: Time‐out from positive reinforcement
Number of subjects: 0
Study 8579350 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 0
Study 2082306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 125
Study 2082306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 125
Study 2082306 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 2 mg
Number of subjects: 125
Study 2082306 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 4 mg
Number of subjects: 125
Study 2082306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 125
Study 2082306 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 125
Study 314724 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (bypass surgery)
Number of subjects: 100
Study 314724 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 100
Study 29306453 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine containing weight loss supplement
Number of subjects: 31
Study 29306453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 27389521 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief integrated intervention
Number of subjects: 290
Study 27389521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine further sessions of integrated treatment
Number of subjects: 290
Study 27389521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine further sessions of alcohol-focused treatment
Number of subjects: 290
Study 27389521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine further sessions of depression-focused treatment
Number of subjects: 290
Study 27389521 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated interventions (incorporating motivational interviewing and cognitive behaviour therapy)
Number of subjects: 290
Study 24284025 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 1245
Study 24284025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1245
Study 22795645 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration to father
Number of subjects: 35
Study 22795645 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration to father
Number of subjects: 35